1.99
Precedente Chiudi:
$1.9267
Aprire:
$1.9
Volume 24 ore:
133.36K
Relative Volume:
2.05
Capitalizzazione di mercato:
$93.75M
Reddito:
$18.11M
Utile/perdita netta:
$-18.95M
Rapporto P/E:
-4.5486
EPS:
-0.4375
Flusso di cassa netto:
-
1 W Prestazione:
+17.75%
1M Prestazione:
+2.06%
6M Prestazione:
+3.11%
1 anno Prestazione:
-27.24%
Adagene Inc Adr Stock (ADAG) Company Profile
Confronta ADAG con altri titoli
Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
---|---|---|---|---|---|---|
![]()
ADAG
Adagene Inc Adr
|
1.99 | 88.09M | 18.11M | -18.95M | 0 | -0.4375 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
472.27 | 120.73B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
564.64 | 61.80B | 14.09B | 4.50B | 2.96B | 39.28 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
328.00 | 42.46B | 2.35B | -269.70M | -75.39M | -2.09 |
![]()
ARGX
Argen X Se Adr
|
591.74 | 35.22B | 2.58B | 1.06B | -1.28B | 16.33 |
![]()
ONC
Beone Medicines Ltd Adr
|
296.46 | 31.99B | 3.81B | -644.79M | -669.77M | -6.24 |
Adagene Inc Adr Stock (ADAG) Upgrades & Downgrades
Data | Azione | Analista | Modifica della valutazione |
---|---|---|---|
2025-01-31 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
2021-06-25 | Iniziato | China Renaissance | Buy |
2021-03-08 | Iniziato | Goldman | Buy |
2021-03-08 | Iniziato | Jefferies | Buy |
2021-03-08 | Iniziato | Morgan Stanley | Overweight |
Adagene Inc Adr Borsa (ADAG) Ultime notizie
Adagene Receives FDA Approval for Phase 2 Trial of Muzastotug in MSS CRC - AInvest
Adagene Announces Regulatory Update on Clinical Development - GlobeNewswire
Adagene (NASDAQ:ADAG) Trading Up 3.8% – Should You Buy? - Defense World
Adagene Receives FDA Guidance On Future Clinical Development Of Experimental Cancer Drug: Retail Turns Optimistic By Stocktwits - Investing.com India
Adagene advances muzastotug to phase 2 trial after FDA meeting By Investing.com - Investing.com South Africa
Adagene Announces Regulatory Update on Clinical Development Plan for Muzastotug in Microsatellite Stable Colorectal Cancer Following Productive Type B Meeting with FDA - MarketScreener
Adagene Advances Clinical Plan for ADG126 in Colorectal Cancer After FDA Meeting - TipRanks
Adagene advances muzastotug to phase 2 trial after FDA meeting - Investing.com
Adagene Announces Regulatory Update on Clinical Development Plan for Muzastotug in Microsatellite Stable Colorectal Cancer Following Productive Type B (End of Phase 1) Meeting with FDA - GlobeNewswire
Adagene's Cancer Drug Shows Breakthrough 29% Response Rate, FDA Fast-Tracks Phase 2 Trial - Stock Titan
Adagene Inc. and ConjugateBio Inc. Partner to Develop Novel Antibody Drug Conjugate - MarketScreener
Adagene to provide antibody to ConjugateBio for bispecific ADC development By Investing.com - Investing.com South Africa
Adagene Partners With ConjugateBio to Develop ADC Programs - MarketScreener
Adagene and ConjugateBio Partner to Develop Novel Antibody Drug Conjugate - GlobeNewswire
Adagene to provide antibody to ConjugateBio for bispecific ADC development - Investing.com
Adagene Enters $30B ADC Market Through Strategic ConjugateBio Partnership for Novel Cancer Therapeutics - Stock Titan
Adagene announces up to $25 million strategic investment from Sanofi - GlobeNewswire
Adagene stock jumps after Sanofi’s $25 million strategic investment By Investing.com - Investing.com India
Adagene (NASDAQ:ADAG) Trading 0.3% Higher – Here’s Why - Defense World
Adagene to present new ADG126 clinical data at ASCO-GI - MSN
Is McKesson (MCK) Outperforming Other Medical Stocks This Year? - Yahoo Finance
Adagene Announces Participation At Leerink’s Global Healthcare Conference 2025 - Bernama
Adagene Inc. (NASDAQ:ADAG) Sees Significant Growth in Short Interest - Defense World
Adagene to Present at Jefferies Global Healthcare Conference 2025 - The Manila Times
Adagene Inc. to Participate in Jefferies Global Healthcare Conference 2025 with Fireside Chat and Investor Meetings - Nasdaq
Exclusive: Adagene Leadership Reveals Latest Antibody Therapeutic Strategy at Major Jefferies Conference - Stock Titan
Adagene (NASDAQ:ADAG) Trading Down 2.1% – Here’s Why - Defense World
Adagene Reports Promising ADG126 Study Results at ASCO - TipRanks
Adagene Announces Updated Data from Phase 1b/2 Study of - GlobeNewswire
New Clinical Data: Adagene's ADG126 Achieves Breakthrough 29% Response Rate in Hard-to-Treat Colorectal Cancer - Stock Titan
ADAGAdagene Inc. Latest Stock News & Market Updates - Stock Titan
Adagene Inc. (NASDAQ:ADAG) Short Interest Update - Defense World
Adagene Appoints John Maraganore, Ph.D. as Executive Advisor - GlobeNewswire
Biotech Pioneer Behind $25B Alnylam Success Story Takes Strategic Role at Adagene's Cancer Drug Mission - Stock Titan
Adagene Announces Upcoming Poster Presentation on Masked Anti-CTLA-4 SAFEbody® ADG126 (Muzastotug) at American Society of Clinical Oncology (ASCO) Annual Meeting - The Manila Times
Adagene Inc. Announces Poster Presentation on ADG126 at ASCO 2025 Conference - Nasdaq
Adagene Announces Upcoming Poster Presentation on Masked - GlobeNewswire
Adagene to Present at Stifel's 2025 Virtual Targeted Oncology Forum - The Manila Times
Adagene to Present at Stifel’s 2025 Virtual Targeted Oncology Forum - GlobeNewswire
Adagene Reveals New Oncology Strategy: CEO Set for Major Investor Presentation - Stock Titan
FY2025 Earnings Estimate for Adagene Issued By HC Wainwright - Defense World
Adagene (NASDAQ:ADAG) Earns “Buy” Rating from HC Wainwright - Defense World
Adagene stock hits 52-week low at $1.62 amid market challenges By Investing.com - Investing.com South Africa
Adagene stock hits 52-week low at $1.62 amid market challenges - Investing.com
Adagene (ADAG) to Release Quarterly Earnings on Thursday - Defense World
Adagene Reports 33% Overall Response Rate in Phase 2 Expansion of Muzastotug for MSS CRC, Highlights Financial Position and Future Milestones - Nasdaq
Adagene Reports Full Year 2024 Financial Results and Provides Corporate Update - GlobeNewswire
Adagene Reveals Breakthrough Cancer Trial Results in 2024 Financial Update - Stock Titan
Adagene Inc. (NASDAQ:ADAG) Short Interest Down 55.9% in February - Defense World
Adagene to Present at 11th Annual Immuno-Oncology 360⁰ Summit - GlobeNewswire
Adagene Inc. to Present ADG126 SAFEbody® Data at 11th Annual Immuno-Oncology 360⁰ Summit in Boston - Nasdaq
Adagene Inc Adr Azioni (ADAG) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):